Celestra Health Raises Profile as a Global Leader in Neurological Digital Biomarkers
July 24, 2025
CELESTRA HEALTH SYSTEMS — Leader in AI-based monitoring of neurological conditions • celestrahealth.com
Celestra Health Systems is an award-winning healthcare software company that has developed a cost-effective and highly sensitive neurological digital biomarker for unobtrusively measuring patient walking quality, under real-world conditions, at 1/100 the cost of conventional solutions.
This past quarter, Celestra Health participated in a number of high-profile events, including the Consortium of MS Centers (CMSC) 2025 conference in Phoenix and the Showcase in the Valley investor event in San Francisco, hosted by Canadian Entrepreneurs in Life Sciences (CELS). We also participated in the International Progressive MS Alliance digital tools workshop in Philadelphia, where we were one of a handful of global firms recognized as leaders in the development of digital tools for progressive forms of MS. We are seeing high levels of interest from pharmaceutical firms, research institutes and neurology clinics, as well as from patients themselves.
We achieved several key milestones this past quarter, including the launch of our large-scale US-based CIDP patient trial with a global pharmaceutical firm and the start of our longitudinal Parkinson’s clinical trial. We continue to gain traction with key customers, while ramping up our marketing and sales activities.
After signing our first major contract with a global pharmaceutical firm in February valued at over $500K, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Direct to Patient trial has now been successfully launched. This represents our largest patient trial to date, with our Operations team on-boarding patients at an unprecedented rate. We have obtained rights to the anonymized patient walking data that we will use to train our algorithms, further strengthening our competitive moat. We have also launched our first longitudinal Parkinson’s disease clinical trial at The Ottawa Hospital, to measure changes in patient condition in response to a novel drug therapy over a 12-month period.
Based on our collaborative work with the Technical University of Dresden (TUD) in Germany, we are now developing sophisticated algorithms for measuring walking quality in an In-Clinic setting, to complement our existing digital biomarker that measures patients under free living conditions in an At-Home environment.
Our objectives for the next quarter include ramping up our business development activities in the US and UK, as we continue to engage with leading pharmaceutical firms and research institutes, as well as launching beta pilots with MS neurology clinics throughout the US. We are also looking forward to participating at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 conference in Barcelona from September 24 to 26, where we will be showcasing our platform in the Exhibitor Hall, as well as presenting our latest research findings. ECTRIMS is the world’s largest MS neurologist event with over 8000 attendees. We are preparing for a seed investment round by early 2026, to fuel our US and European sales expansion.
To learn more, visit celestrahealth.com.